Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced ...

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing ...

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move ...

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset ...

Pfizer said today it would acquire weight-loss drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment ...

(Bloomberg) — Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

Trump said Pfizer agreed to discounts between 50% and 100% for drugs it puts on the new website, according to the Journal. The company said the majority of its “primary care treatments and some select ...

President Donald Trump announced Tuesday that he has secured a deal with drugmaker Pfizer to lower its drug prices. There will also be a TrumpRx website.

Pfizer PFE2.33%increase; green up pointing triangle has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera MTSR 62.67%increase; green up pointing triangle in a deal that returns ...